Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2023
>
Merck and Proxygen partner in deal worth up to $2.5bn
Merck and Proxygen partner in deal worth up to $2.5bn
Read also
Adjunctive Use Approved CBD
Study: Adjunctive Use of FDA-Approved CBD Formulation Reduces Seizures in Pediatric Patients With Rett Syndrome
Sanofi’s Tzield
Sanofi’s Tzield gains approval in China for T1D management
Capricor
Capricor refutes FDA’s DMD deramiocel rejection in public statement
Medison and Ipsen’s Bylvay
Health Canada approves Medison and Ipsen’s Bylvay to treat ALGS
